Business Description
Clover Biopharmaceuticals Ltd
ISIN : KYG2280A1076
Total Employee Number:
257Compare
Compare
Traded in other countries / regions
02197.Hong Kong Index Membership
Hong Kong Stock Connect IPO Date
2021-11-05Description
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 26.95 | |||||
Equity-to-Asset | -3.93 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -37.3 | |||||
Beneish M-Score | -5.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 59.9 | |||||
3-Year EPS without NRI Growth Rate | 55.1 | |||||
3-Year FCF Growth Rate | 54.5 | |||||
3-Year Book Growth Rate | -38.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.42 | |||||
9-Day RSI | 84.06 | |||||
14-Day RSI | 75.19 | |||||
3-1 Month Momentum % | -46.15 | |||||
6-1 Month Momentum % | -33.18 | |||||
12-1 Month Momentum % | 129.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.19 | |||||
Quick Ratio | 0.19 | |||||
Cash Ratio | 0.16 | |||||
Days Inventory | 5169.52 | |||||
Days Sales Outstanding | 1463.84 | |||||
Days Payable | 53758.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 5.16 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.2 | |||||
Operating Margin % | -6222.95 | |||||
Net Margin % | -5878.69 | |||||
EBITDA Margin % | -5088.08 | |||||
FCF Margin % | -5579.34 | |||||
OCF Margin % | -5578.4 | |||||
ROA % | -33.42 | |||||
ROIC % | -12.44 | |||||
3-Year ROIIC % | -335.03 | |||||
ROC (Joel Greenblatt) % | -197.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.98 | |||||
PS Ratio | 790 | |||||
EV-to-EBIT | -11.87 | |||||
EV-to-Forward-EBIT | 0.01 | |||||
EV-to-EBITDA | -13.69 | |||||
EV-to-Forward-EBITDA | 0.01 | |||||
EV-to-Revenue | 696.74 | |||||
EV-to-FCF | -12.49 | |||||
Earnings Yield (Greenblatt) % | -8.42 | |||||
FCF Yield % | -6.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clover Biopharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 3.834 | ||
| EPS (TTM) (HK$) | -0.175 | ||
| Beta | 2.5333 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.56 | ||
| Volatility % | 179.65 | ||
| 14-Day RSI | 75.19 | ||
| 14-Day ATR (HK$) | 0.190489 | ||
| 20-Day SMA (HK$) | 1.94675 | ||
| 12-1 Month Momentum % | 129.69 | ||
| 52-Week Range (HK$) | 0.62 - 3.2 | ||
| Shares Outstanding (Mil) | 1,297.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clover Biopharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clover Biopharmaceuticals Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-27 | In 13 days | ||
| Guidance call for 2026 | 2026-06-24 | 1.79 (+1.70%) | ||
| General meeting for 2025 | 2026-06-18 10:00 | 1.61 (+21.05%) | ||
| Guidance call for 2026 | 2026-05-26 | 2.56 (-1.54%) | ||
| Post Annual-Report Investment Forum of Soochow Securities | 2026-05-14 | 2.73 (-3.19%) | ||
| Annual report for 2025 | 2026-04-23 | 3.11 (+2.64%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 2.63 (+9.58%) | ||
| Clover Biopharma (2197 HK) RSV Vaccine Candidates Portfolio Clinical Trial Updates | 2025-10-15 10:30 | 2.82 (-5.69%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 0.92 (+2.22%) | ||
| General meeting for 2024 | 2025-06-19 10:00 | 0.27 (+1.92%) |
Show
Entries
Clover Biopharmaceuticals Ltd Frequently Asked Questions
What is Clover Biopharmaceuticals Ltd(HKSE:02197)'s stock price today?
The current price of HKSE:02197 is HK$2.37. The 52 week high of HKSE:02197 is HK$3.20 and 52 week low is HK$0.62.
When is next earnings date of Clover Biopharmaceuticals Ltd(HKSE:02197)?
The next earnings date of Clover Biopharmaceuticals Ltd(HKSE:02197) is 2026-08-27 Est..
Does Clover Biopharmaceuticals Ltd(HKSE:02197) pay dividends? If so, how much?
Clover Biopharmaceuticals Ltd(HKSE:02197) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Clover Biopharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers